pharma · MPS IIIA · Epidermolysis Bullosa · ABEO
ABEONA THERAPEUTICS
ABEONA THERAPEUTICS INC.
ABEONA THERAPEUTICS is a pharma organization headquartered in Cleveland, USA. It trades on NYSE under ticker ABEO. Primary therapeutic focus areas include MPS IIIA, Epidermolysis Bullosa, Onychomycosis, Epidermolysis Bul
Cleveland, USA HQ
2015 Founded
228 Employees
Public company Type
ABEO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cleveland, USA
- Founded
- 2015
- Employees
- 228
- Programs
- 8
- Drugs
- 3
- Patents
- 0
rAAV9.CMV.hNAGLU
Phase 2 · mab · Mucopolysaccharidosis Type 3 B
rAAV9.CMV.hNAGLU for Mucopolysaccharidosis Type 3 B is a Phase 2 program (mab) at ABEONA THERAPEUTICS INC. with 1 ClinicalTrials.gov record(s).
Internal code ABT-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ABEONA THERAPEUTICS INC.
- Phase
- Phase 2
- Modality
- mab
- Indication
- Mucopolysaccharidosis Type 3 B
- Status
- terminated
- Trials
- 1